Organon & Co. Aktie News

Organon remains a buy as the stock trades at distressed valuations despite stable fundamentals and progress on debt reduction. OGN's Women's Health and Biosimilars segments drive growth, offsetting revenue declines from loss of exclusivity in established brands like Atozet. Management's focus on operational efficiency and aggressive deleveraging, aided by a dividend cut, positions OGN for a pot...

SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--European Commission Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars.

NEW YORK , Sept. 9, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Organon & Co. (NYSE: OGN)  breached their fiduciary duties to shareholders.

SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--FDA Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp).

SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of Organon & Co. (NYSE: OGN). Investors who purchased shares of Organon & Co. (NYSE: OGN) prior to October 2024 and continue to hold any of those NYSE: OGN shares, also have certain options and should contact the Shareholders Foundation at mail@sharehold...

Organon shares are very cheap, but weak growth, high debt, and a lack of clear catalysts make them a value trap rather than a bargain. Revenue is stagnating as new products only offset legacy declines; cost-cutting helps margins, but can't reverse the downward trend in earnings. Valuation discounts already reflect worst-case scenarios; fair value is around $9 per share, leaving little upside un...

Organon & Co.'s shrinking revenues, heavy debt, and slashed dividend make it an unattractive investment despite its low valuation metrics. The Established Brands division is in decline, and new products like Emgality and VTAMA are not offsetting losses from older drugs. Women's Health and Biosimilars show some growth, but not enough to reverse the overall negative trend or justify optimism.

Organon (OGN) Fiscal Q2 Revenue Beats 1%